[SCHEDULE 13G/A] Rocket Pharmaceuticals, Inc. SEC Filing
Rocket Pharmaceuticals disclosure shows that Maverick-affiliated entities and Lee S. Ainslie beneficially hold 8,363,813 shares of common stock, equal to 7.8% of the company based on 107,737,919 shares outstanding. The reported holdings arise from multiple funds and accounts: Maverick Fund USA, Ltd. (1,686,548 shares); Maverick Fund II, Ltd. (1,727,675); Maverick Long Enhanced Fund, Ltd. (1,930,078); Maverick HP, L.P. (1,726,954); Maverick Long Fund, Ltd. (958,547); and separately managed accounts (334,011).
Maverick is identified as the investment adviser with investment discretion over these client accounts, Maverick Capital Management is the general partner, and Lee S. Ainslie III is the manager. The filing reports no sole voting or dispositive power and shared voting and dispositive power over all 8,363,813 shares, indicating a significant institutional stake without unilateral control.
La comunicazione di Rocket Pharmaceuticals mostra che entit脿 affiliate a Maverick e Lee S. Ainslie detengono beneficiariamente 8,363,813 azioni ordinarie, pari al 7.8% della societ脿 su un totale di 107,737,919 azioni in circolazione. Le partecipazioni dichiarate provengono da pi霉 fondi e conti: Maverick Fund USA, Ltd. (1,686,548 azioni); Maverick Fund II, Ltd. (1,727,675); Maverick Long Enhanced Fund, Ltd. (1,930,078); Maverick HP, L.P. (1,726,954); Maverick Long Fund, Ltd. (958,547); e conti gestiti separatamente (334,011).
Maverick 猫 indicata come consulente d'investimento con discrezione sugli investimenti di questi conti, Maverick Capital Management 猫 il partner generale e Lee S. Ainslie III 猫 il gestore. La comunicazione riporta nessun potere esclusivo di voto o di disposizione e potere condiviso di voto e di disposizione su tutte le 8,363,813 azioni, segnalando una partecipazione istituzionale significativa senza controllo unilaterale.
La comunicaci贸n de Rocket Pharmaceuticals muestra que entidades vinculadas a Maverick y Lee S. Ainslie poseen beneficiariamente 8,363,813 acciones ordinarias, equivalentes al 7.8% de la compa帽铆a sobre un total de 107,737,919 acciones en circulaci贸n. Las participaciones declaradas provienen de varios fondos y cuentas: Maverick Fund USA, Ltd. (1,686,548 acciones); Maverick Fund II, Ltd. (1,727,675); Maverick Long Enhanced Fund, Ltd. (1,930,078); Maverick HP, L.P. (1,726,954); Maverick Long Fund, Ltd. (958,547); y cuentas gestionadas por separado (334,011).
Maverick figura como asesor de inversi贸n con discreci贸n sobre las inversiones de estas cuentas de clientes, Maverick Capital Management es el socio general y Lee S. Ainslie III es el gestor. El informe se帽ala ning煤n poder exclusivo de voto o disposici贸n y poder compartido de voto y disposici贸n sobre las 8,363,813 acciones, lo que indica una participaci贸n institucional importante sin control unilateral.
Rocket Pharmaceuticals鞚� 瓿奠嫓鞐� 霐半ゴ氅� Maverick 鞐瓣硠 旮瓣磤霌り臣 Lee S. Ainslie電� 靷嫟靸� 8,363,813欤�鞚� 氤错喌欤茧ゼ 氤挫湢頃橁碃 鞛堨溂氅�, 齑� 氚滍枆欤检嫕靾� 107,737,919欤� 旮办鞙茧 須岇偓 歆�攵勳潣 7.8%鞐� 頃措嫻頃╇媹雼�. 鞁犼碃霅� 氤挫湢電� 鞐煬 韼�霌滌檧 瓿勳鞐愳劀 氚滌儩頃╇媹雼�: Maverick Fund USA, Ltd. (1,686,548欤�); Maverick Fund II, Ltd. (1,727,675); Maverick Long Enhanced Fund, Ltd. (1,930,078); Maverick HP, L.P. (1,726,954); Maverick Long Fund, Ltd. (958,547); 氤勲弰 鞖挫毄 瓿勳(334,011).
瓿奠嫓鞐愳劀電� Maverick鞚� 鞚措摛 瓿犼皾 瓿勳鞚� 韴瀽 鞛焿鞚� 臧�歆� 韴瀽鞛愲靷, Maverick Capital Management臧� 鞚茧皹 韺岉姼雱堨澊氅� Lee S. Ainslie III臧� 毵る媹鞝�搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 頃措嫻 鞁犼碃電� 氇摖 8,363,813欤检棎 雽�頃� 雼弲 鞚橁舶甓� 霕愲姅 觳橂秳甓� 鞐嗢潓瓿� 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓� 氤挫湢鞚� 氤搓碃頃橁碃 鞛堨柎 雼弲 韱奠牅 鞐嗢澊 靸侂嫻頃� 旮瓣磤 歆�攵勳潉 氤挫湢頃橁碃 鞛堨潓鞚� 雮橅儉雰呺媹雼�.
La communication de Rocket Pharmaceuticals indique que des entit茅s affili茅es 脿 Maverick et Lee S. Ainslie d茅tiennent b茅n茅ficiairement 8,363,813 actions ordinaires, soit 7.8% de la soci茅t茅 sur la base de 107,737,919 actions en circulation. Les participations d茅clar茅es proviennent de plusieurs fonds et comptes : Maverick Fund USA, Ltd. (1,686,548 actions) ; Maverick Fund II, Ltd. (1,727,675) ; Maverick Long Enhanced Fund, Ltd. (1,930,078) ; Maverick HP, L.P. (1,726,954) ; Maverick Long Fund, Ltd. (958,547) ; et des comptes g茅r茅s s茅par茅ment (334,011).
Maverick est identifi茅 comme le conseiller en investissement disposant de la discr茅tion d'investissement sur ces comptes clients, Maverick Capital Management est le commandit茅 et Lee S. Ainslie III en est le gestionnaire. Le d茅p么t indique aucun pouvoir de vote ou de disposition exclusif et un pouvoir de vote et de disposition partag茅 sur l'ensemble des 8,363,813 actions, traduisant une participation institutionnelle significative sans contr么le unilat茅ral.
Die Offenlegung von Rocket Pharmaceuticals zeigt, dass Maverick-nahe Einheiten und Lee S. Ainslie wirtschaftlich 8,363,813 Aktien des Stammkapitals halten, was bei insgesamt 107,737,919 ausstehenden Aktien 7.8% des Unternehmens entspricht. Die gemeldeten Best盲nde stammen aus mehreren Fonds und Konten: Maverick Fund USA, Ltd. (1,686,548 Aktien); Maverick Fund II, Ltd. (1,727,675); Maverick Long Enhanced Fund, Ltd. (1,930,078); Maverick HP, L.P. (1,726,954); Maverick Long Fund, Ltd. (958,547); sowie separat verwaltete Konten (334,011).
Maverick wird als Anlageberater mit Investitionsdiscretion f眉r diese Kundenkonten genannt, Maverick Capital Management ist der General Partner und Lee S. Ainslie III der Manager. Die Meldung gibt an, dass f眉r alle 8,363,813 Aktien keine alleinige Stimm- oder Verf眉gungsbefugnis besteht, sondern gemeinsame Stimm- und Verf眉gungsbefugnis, was auf eine bedeutende institutionelle Beteiligung ohne einseitige Kontrolle hinweist.
- None.
- None.
Insights
TL;DR Maverick and affiliates hold a material 7.8% stake (8.36M shares), a notable institutional position but not controlling.
The filing documents a substantial passive institutional stake across multiple Maverick funds and managed accounts totaling 8,363,813 shares, representing 7.8% of the outstanding common stock (107,737,919 shares). All power is reported as shared rather than sole, so while this is large enough to warrant attention from investors and the company, it does not convey unilateral voting or disposition control. The structure鈥攁dvisory relationships and general partner/manager roles鈥攃larifies why beneficial ownership is attributed to both the firm and Mr. Ainslie.
TL;DR A meaningful institutional stake is disclosed, but lack of sole voting power limits immediate governance control.
The Schedule 13G shows coordinated beneficial ownership by Maverick entities and Lee S. Ainslie totaling 8,363,813 shares (7.8%). The report specifies shared voting and dispositive power with no sole authority, implying influence potential via engagement or coalition-building rather than direct control. For governance impact, this position is material enough to matter in activist or engagement scenarios, but the filing does not indicate any group formation, solicitation, or intent to influence control.
La comunicazione di Rocket Pharmaceuticals mostra che entit脿 affiliate a Maverick e Lee S. Ainslie detengono beneficiariamente 8,363,813 azioni ordinarie, pari al 7.8% della societ脿 su un totale di 107,737,919 azioni in circolazione. Le partecipazioni dichiarate provengono da pi霉 fondi e conti: Maverick Fund USA, Ltd. (1,686,548 azioni); Maverick Fund II, Ltd. (1,727,675); Maverick Long Enhanced Fund, Ltd. (1,930,078); Maverick HP, L.P. (1,726,954); Maverick Long Fund, Ltd. (958,547); e conti gestiti separatamente (334,011).
Maverick 猫 indicata come consulente d'investimento con discrezione sugli investimenti di questi conti, Maverick Capital Management 猫 il partner generale e Lee S. Ainslie III 猫 il gestore. La comunicazione riporta nessun potere esclusivo di voto o di disposizione e potere condiviso di voto e di disposizione su tutte le 8,363,813 azioni, segnalando una partecipazione istituzionale significativa senza controllo unilaterale.
La comunicaci贸n de Rocket Pharmaceuticals muestra que entidades vinculadas a Maverick y Lee S. Ainslie poseen beneficiariamente 8,363,813 acciones ordinarias, equivalentes al 7.8% de la compa帽铆a sobre un total de 107,737,919 acciones en circulaci贸n. Las participaciones declaradas provienen de varios fondos y cuentas: Maverick Fund USA, Ltd. (1,686,548 acciones); Maverick Fund II, Ltd. (1,727,675); Maverick Long Enhanced Fund, Ltd. (1,930,078); Maverick HP, L.P. (1,726,954); Maverick Long Fund, Ltd. (958,547); y cuentas gestionadas por separado (334,011).
Maverick figura como asesor de inversi贸n con discreci贸n sobre las inversiones de estas cuentas de clientes, Maverick Capital Management es el socio general y Lee S. Ainslie III es el gestor. El informe se帽ala ning煤n poder exclusivo de voto o disposici贸n y poder compartido de voto y disposici贸n sobre las 8,363,813 acciones, lo que indica una participaci贸n institucional importante sin control unilateral.
Rocket Pharmaceuticals鞚� 瓿奠嫓鞐� 霐半ゴ氅� Maverick 鞐瓣硠 旮瓣磤霌り臣 Lee S. Ainslie電� 靷嫟靸� 8,363,813欤�鞚� 氤错喌欤茧ゼ 氤挫湢頃橁碃 鞛堨溂氅�, 齑� 氚滍枆欤检嫕靾� 107,737,919欤� 旮办鞙茧 須岇偓 歆�攵勳潣 7.8%鞐� 頃措嫻頃╇媹雼�. 鞁犼碃霅� 氤挫湢電� 鞐煬 韼�霌滌檧 瓿勳鞐愳劀 氚滌儩頃╇媹雼�: Maverick Fund USA, Ltd. (1,686,548欤�); Maverick Fund II, Ltd. (1,727,675); Maverick Long Enhanced Fund, Ltd. (1,930,078); Maverick HP, L.P. (1,726,954); Maverick Long Fund, Ltd. (958,547); 氤勲弰 鞖挫毄 瓿勳(334,011).
瓿奠嫓鞐愳劀電� Maverick鞚� 鞚措摛 瓿犼皾 瓿勳鞚� 韴瀽 鞛焿鞚� 臧�歆� 韴瀽鞛愲靷, Maverick Capital Management臧� 鞚茧皹 韺岉姼雱堨澊氅� Lee S. Ainslie III臧� 毵る媹鞝�搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 頃措嫻 鞁犼碃電� 氇摖 8,363,813欤检棎 雽�頃� 雼弲 鞚橁舶甓� 霕愲姅 觳橂秳甓� 鞐嗢潓瓿� 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓� 氤挫湢鞚� 氤搓碃頃橁碃 鞛堨柎 雼弲 韱奠牅 鞐嗢澊 靸侂嫻頃� 旮瓣磤 歆�攵勳潉 氤挫湢頃橁碃 鞛堨潓鞚� 雮橅儉雰呺媹雼�.
La communication de Rocket Pharmaceuticals indique que des entit茅s affili茅es 脿 Maverick et Lee S. Ainslie d茅tiennent b茅n茅ficiairement 8,363,813 actions ordinaires, soit 7.8% de la soci茅t茅 sur la base de 107,737,919 actions en circulation. Les participations d茅clar茅es proviennent de plusieurs fonds et comptes : Maverick Fund USA, Ltd. (1,686,548 actions) ; Maverick Fund II, Ltd. (1,727,675) ; Maverick Long Enhanced Fund, Ltd. (1,930,078) ; Maverick HP, L.P. (1,726,954) ; Maverick Long Fund, Ltd. (958,547) ; et des comptes g茅r茅s s茅par茅ment (334,011).
Maverick est identifi茅 comme le conseiller en investissement disposant de la discr茅tion d'investissement sur ces comptes clients, Maverick Capital Management est le commandit茅 et Lee S. Ainslie III en est le gestionnaire. Le d茅p么t indique aucun pouvoir de vote ou de disposition exclusif et un pouvoir de vote et de disposition partag茅 sur l'ensemble des 8,363,813 actions, traduisant une participation institutionnelle significative sans contr么le unilat茅ral.
Die Offenlegung von Rocket Pharmaceuticals zeigt, dass Maverick-nahe Einheiten und Lee S. Ainslie wirtschaftlich 8,363,813 Aktien des Stammkapitals halten, was bei insgesamt 107,737,919 ausstehenden Aktien 7.8% des Unternehmens entspricht. Die gemeldeten Best盲nde stammen aus mehreren Fonds und Konten: Maverick Fund USA, Ltd. (1,686,548 Aktien); Maverick Fund II, Ltd. (1,727,675); Maverick Long Enhanced Fund, Ltd. (1,930,078); Maverick HP, L.P. (1,726,954); Maverick Long Fund, Ltd. (958,547); sowie separat verwaltete Konten (334,011).
Maverick wird als Anlageberater mit Investitionsdiscretion f眉r diese Kundenkonten genannt, Maverick Capital Management ist der General Partner und Lee S. Ainslie III der Manager. Die Meldung gibt an, dass f眉r alle 8,363,813 Aktien keine alleinige Stimm- oder Verf眉gungsbefugnis besteht, sondern gemeinsame Stimm- und Verf眉gungsbefugnis, was auf eine bedeutende institutionelle Beteiligung ohne einseitige Kontrolle hinweist.
FAQ
How many Rocket Pharmaceuticals (RCKT) shares do Maverick and affiliates own?
What percentage of RCKT does Maverick's position represent?
Do Maverick or Lee S. Ainslie have sole voting control over these shares?
Which Maverick funds hold the reported shares?
Does this filing indicate an intent to influence control of Rocket Pharmaceuticals?
